Autolus Therapeutics Stock Price on September 23, 2024
| AUTL Stock | USD 2.98 0.04 1.36% |
Below is the normalized historical share price chart for Autolus Therapeutics extending back to June 22, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Autolus Therapeutics stands at 2.98, as last reported on the 26th of November, with the highest price reaching 3.08 and the lowest price hitting 2.93 during the day.
If you're considering investing in Autolus Stock, it is important to understand the factors that can impact its price. Autolus Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0671, which signifies that the company had a -0.0671% return per unit of risk over the last 3 months. Autolus Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Autolus Therapeutics' Standard Deviation of 4.66, mean deviation of 3.39, and Risk Adjusted Performance of (0.05) to double-check the risk estimate we provide.
At this time, Autolus Therapeutics' Total Stockholder Equity is quite stable compared to the past year. Common Stock is expected to rise to 9,660 this year, although the value of Other Stockholder Equity will most likely fall to about 545 M. . At this time, Autolus Therapeutics' Price To Sales Ratio is quite stable compared to the past year. Price Sales Ratio is expected to rise to 980.68 this year, although the value of Price Earnings Ratio will most likely fall to (5.64). Autolus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 22nd of June 2018 | 200 Day MA 4.4291 | 50 Day MA 3.7892 | Beta 2.039 |
Autolus |
Sharpe Ratio = -0.0671
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AUTL |
Estimated Market Risk
| 4.78 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Autolus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Autolus Therapeutics by adding Autolus Therapeutics to a well-diversified portfolio.
Price Book 1.6404 | Enterprise Value Ebitda 0.0326 | Price Sales 77.5343 | Shares Float 131.6 M | Wall Street Target Price 10.45 |
Related Headline
Cullinan Oncology Headline on 23rd of September 2024
Cullinan Therapeutics Files Investigational New Drug Applica... by news.google.com
Cullinan Therapeutics Files Investigational New Drug Application with FDA for CLN-978 for Treatment of Systemic Lupus Erythematosus Lupus Foundation of America
Autolus Therapeutics Valuation on September 23, 2024
It is possible to determine the worth of Autolus Therapeutics on a given historical date. On September 23, 2024 Autolus was worth 3.7 at the beginning of the trading date compared to the closed value of 3.5. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Autolus Therapeutics stock. Still, in general, we apply an absolute valuation method to find Autolus Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Autolus Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Autolus Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 3.82 | 3.86 | 3.64 | 3.73 | 747,976 | |
09/23/2024 | 3.70 | 3.75 | 3.48 | 3.50 | 986,529 |
| 3.53 | 3.61 | 3.42 | 3.51 | 523,626 |
| Backtest Autolus Therapeutics | | | Autolus Therapeutics History | | | Autolus Therapeutics Valuation | Previous | Next |
Autolus Therapeutics Trading Date Momentum on September 23, 2024
| On September 24 2024 Autolus Therapeutics was traded for 3.51 at the closing time. The top price for the day was 3.61 and the lowest listed price was 3.42 . The trading volume for the day was 523.6 K. The trading history from September 24, 2024 was a factor to the next trading day price upswing. The overall trading delta against the next closing price was 0.29% . The overall trading delta against the current closing price is 13.43% . |
Autolus Therapeutics Fundamentals Correlations and Trends
By evaluating Autolus Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Autolus Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Autolus financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Autolus Therapeutics Stock history
Autolus Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Autolus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Autolus Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Autolus Therapeutics stock prices may prove useful in developing a viable investing in Autolus Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 173.9 M | 182.6 M | |
| Net Loss | -134 M | -127.3 M |
Autolus Therapeutics Quarterly Net Working Capital |
|
Autolus Therapeutics Stock Technical Analysis
Autolus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Autolus Therapeutics Period Price Range
Low | November 26, 2024
| High |
0.00 | 0.00 |
Autolus Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Autolus Therapeutics November 26, 2024 Market Strength
Market strength indicators help investors to evaluate how Autolus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Autolus Therapeutics shares will generate the highest return on investment. By undertsting and applying Autolus Therapeutics stock market strength indicators, traders can identify Autolus Therapeutics entry and exit signals to maximize returns
Autolus Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Autolus Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Autolus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Autolus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (1.09) | |||
| Treynor Ratio | (0.17) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.